Currently out of the existing stock ratings of Reni Benjamin, 195 are a BUY (86.28%), 30 are a HOLD (13.27%), 1 are a SELL (0.44%).

Reni Benjamin

Work Performance Price Targets & Ratings Chart

Analyst Reni Benjamin, carries an average stock price target met ratio of 43.81% that have a potential upside of 54.39% achieved within 174 days.

Reni Benjamin’s has documented 408 price targets and ratings displayed on 32 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on BCYC, Bicycle Therapeutics Ltd at 31-Oct-2025.

Wall Street Analyst Reni Benjamin

Analyst best performing recommendations are on SANA (SANA BIOTECHNOLOGY).
The best stock recommendation documented was for PRLD (PRELUDE THERAPEUTICS ) at 8/18/2025. The price target of $3 was fulfilled within 77 days with a profit of $2.06 (219.15%) receiving and performance score of 28.46.

Average potential price target upside

of $40.83 (68.31%) on BPMC (BLUEPRINT MEDICINES CORP).
of $26.61 (37.12%) on INCY (YTE).
of $17.03 (11.08%) on SGEN (SEAGEN).

BCYC Bicycle Therapeutics Ltd BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC EFTR Effector Therapeutics INBX Inhibrx INCY yte IOVA Iovance Biotherapeutics SGEN Seagen STRO Sutro Biopharma VYGR Voyager Therapeutics ALLO Allogene Therapeutics CGEN Compugen KURA Kura Oncology ACET Adicet Bio CTIC CTi Biopharma Corp RGNX Regenxbio ADAP Adaptimmune Therapeutics Plc ADVM Adverum Biotechnologies BCAB Bioatla CUE Cue Biopharma SPPI Spectrum Pharmaceuticals URGN UroGen Pharma Ltd AMAM Ambrx Biopharma American Depositary Shares LVTX LAVA Therapeutics NV SANA Sana Biotechnology VSTM Verastem HOWL Werewolf Therapeutics PRLD Prelude Therapeutics AKBA Akebia Ther IDRA Idera Pharmaceuticals SMMT Summit Therapeutics PLC TIL Instil Bio

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Gregory Renza (TRUIST)